Advancing Medicine with AI Technologies
Bayer and Iambic Launch AI Drug Discovery Partnership
The collaboration leverages Iambic’s AI platform to find new treatments for challenging medical targets.
A 3D molecular structure glowing on a digital display in a modern pharmaceutical research lab.
Photo: Avantgarde News
Bayer and Iambic Therapeutics have formed a strategic partnership to develop new medicines using artificial intelligence [1]. The collaboration will focus on discovering small molecule drugs for medical targets that are typically difficult to reach [1].
Iambic will provide access to its AI-driven platform, which includes the Enchant and NeuralPLexer technologies [1]. These tools are designed to shorten research and development timelines and improve drug discovery outcomes [1].
Editorial notes
Transparency note
AI assisted drafting. Human edited and reviewed.
- AI assisted
- Yes
- Human review
- Yes
- Last updated
Risk assessment
The provided source list contains only one independent domain (iambic.ai), failing the requirement for at least three independent domains.
Sources
Related stories
View all
Topics
About the author
Avantgarde News Desk covers advancing medicine with ai technologies and editorial analysis for Avantgarde News.